JPPS 2008; 5(1): 22-26 ORIGINAL ARTICLE

EFFICACY OF TOPIRAMATE AS AN ADJUNCT MEDICATION IN HEROIN WITHDRAWAL:

A RANDOMIZED CONTROL TRIAL

Naghmeh Mokhber, Atefeh Soltanifar, Mahdi Talebi

# ABSTRACT

**Objective:** To compare the efficacy of Topiramate in reducing Heroin withdrawal symptoms in Iranian paients.

**Design:** Double blind placebo-controlled trial.

**Place & Duration of Study:** Study was conducted in Ibn-e-Sina Hospital, Mashad, Iran in a period of two years i.e., 2006-07.

**Subjects & Methods:** The study was carried out on 149 patients with Heroin dependency (74 in Topiramate group and 75 in Treatment as usual group) using 2 standard questionnaires for assessment of with- drawal symptoms, Subjective opiate withdrawal scale (SOWS) and objetive opiate withdrawal scale (OOWS). Information was analyzed by chi-square test for qualitative variables and T-test & Mann-Whitney for quantitative variables in SPSS software.

**Results:** 22 subjects were excluded from the study. Both groups had no significant differences in age, sex, education, number of previous withdrawal and past history of other drug use. Results indicated decrease in objective withdrawal symptom, significant in 3rd (p=0.000), 5th (p=0.004) and 7th (p=0.026) day and subjective withdrawal symptom significant in 3rd (p=0.000) day in topiramate group.

**Conclusions:** Our study showed that Topiramate can use for control of withdrawal symptom in patient with Heroin dependency.

**Key words:** Topiramate, Detoxification, Withdrawal, Opium, Heroin.

# INTRODUCTION

Opioid dependency is a maladaptive pattern of using opioids that besides its harmful personal effects, has many social adverse consequences such as unem- ployment, divorce, economic deprivation and illegal acts1. Therefore different specialists and especially psychiatrists have paid a considerable attention toward this problem.

Substance dependency includes behavioral (focusing on seeking behaviors and their related evidence) and somatic dependency (physiologic effects of repetitive pattern of substance use) and its treatment should be directed to these 2 dimensions.

Detoxification is considered as one important phase of substance dependency treatment. Many

**Naghmeh Mokhber,** Associate Professor of Psychiatry, Mashad University of Medical Sciences, Iran.

**Atefeh Soltanifar,** Assistant Professor of Psychiatry, Mashad University of Medical Sciences, Iran.

**Mahdi Talebi,** Resident in Psychiatry, Mashad University of Medical Sciences, Iran.

**Correspondence:**

**Dr. Naghmeh Mokhber**

patients delay substance abstinence because of their inability to tolerate the withdrawal symptoms. So clinicians try to safely ameliorate these symptoms2,3.

Patients who use the substances with short half lives such as Heroin4 have more problems in the with- drawal of these opioids.

Noradrenergic neurons have an important role in causing withdrawal symptoms. Clonidine, an alpha 2 adrenergic agonist, is a common used drug for decreas- ing the noradrenergic hyperactivity and reducing these symptoms5. Clonidine is not an efficient drug in man- agement of many symptoms such as anxiety, restless- ness, muscular pain and craving6. Clonidine use also has been limited because of its side effects including hypotension and sedation in patients with acute cardiac disease and moderate to severe hypotension7.

Methadone, an opioid receptor agonist, could be used for reducing the withdrawal symptoms at tapered doses, but its most important problems include the long term treatment period and difficulties in providing Methadone8.Therefore, because of suboptimal efficacy of Clonidine and disliking the use of opioid agonists by some patients, many clinical trials were carried out to

examine the efficacy of other drugs such as Nimodipine9,Mianserin10 and Doxepine11 in the opioid withdrawal phase.

With the recognition of kindling and its probable role in substance abuse12 the importance of anticonvul- sants in the treatment of substance dependency was revealed. Anticonvulsants have no dependency risk and are useful for the treatment of comorbid psychiatric dis- orders in these patients13. Efficacy of carbamazepine in detoxification of benzodiazepines, alcohol and opioids and in reducing cocaine consumption has been sup- ported in some studies13. Valproate Na has been pro- posed as a treatment of alcohol withdrawal and reduc- ing cocaine consumption, but it seems not to be effec- tive in the treatment of benzodiazepine detoxification13.

Excitory amino acid (EAA) antagonists inhibit the process of morphine tolerance and dependence14 and Lamotrigine suppress the release of EAA with its effect on Na channels15. Some data show the efficacy of Lamotrigine in the opiate dependency16.

One study in 2004 assessed the efficacy of Gabapentine in the treatment of Heroin withdrawal in 7 outpatients. Results showed that it was effective in con- trolling the withdrawal symptoms .The limitations of this study were the small sample size and lack of structured scale for assessment of withdrawal symptoms17. An- other study in 2004 indicated that adding carbamazepine

–minserine to usual medications was effective in reduc- ing the opiate withdrawal symptoms18.

Topiramate is an antiepileptic drug that has been shown to be effective in opiate withdrawal treatment in a few researches, but these studies had small sample sizes and did not have an assessment scale for measuring the withdrawal symptoms. So, we decided to examine the efficacy of Topiramate in reducing Heroin withdrawal symptoms in Iranian patients.

# SUBJECTS AND METHODS

This was a double blind placebo-controlled trial that was carried out on 149 patients with Heroin depen- dency in Ibne –sina hospital–Mashhad in the period of 2 years (2006-2007).

The sample was selected from admitted patients with Heroin dependency for detoxification who had the inclusion criteria for the study and willingness to coop- erate. Demographic characteristics, history of previous or current substance use and history of psychiatric and somatic disorders were collected through a semi-struc- tured interview by a psychiatrist. Patients were randomly divided into Topiramate and placebo groups. In the First group, subjects received clonidine (0.2-0.8mg min o.6), Ibuprofen (1200-2400 mg min 1800), lorazepam (2-6

mg min 4), amitriptyline (25-75 mg min 50) and Topiramate with a starting dose of 75-100 mg that was added up to min 150-200 mg after 3 days and continued until the end of treatment. The placebo group took the same regimen without Topiramate that was replaced with a placebo in the same shape and color of Topi- ramate. During the 10 days of hospitalization, withdrawal

Table1

Demographic data of patients referred for opiate detoxification

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Groups** | **Mean age** | **Sex ratio M/F** | **Job status** | | **Marital status** | | |
| **Unemployed** | **Employed** | **Married** | **Single** | **Divorced** |
| Topiramate | 24.02 | 5.62 | 35 | 32 | 9 | 47 | 11 |
| Placebo | 23.78 | 7.53 | 36 | 24 | 16 | 36 | 8 |
|  | P=0.147 t=0.404 | P=0.419 X2=0.654 | P=0.379 X2=0.773 | | P=0.1172 X2=3.516 | | |

Table 2

History of substance use in referred patients for detoxification

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Groups** | **Mean time of substance**  **dependency** | **Ways of consumption** | | | **Number of abstinences** | | **History of using other substances** | | |
| **Inh** | **Inj** | **Inh+inj** | **<3** | **>3** | **AI.\*** | **H.** | **Op.** |
| Topiramate | 43.34  sd=21 | 51 | 8 | 8 | 56 | 11 | 16 | 13 | 25 |
| Placebo | 36.20  sd=18 | 42 | 12 | 6 | 45 | 15 | 14 | 12 | 24 |
|  | P=0.129 Z=-1.518 | P=0.455 X2=1.576 | | | P=0.231 X2=1.432 | | P=0.94 X2=0.0 | P=0.92 X2=0.0 | P=0.756 X2=0.090 |

Inh = Inhalation Al=Alcohol Inj=injection H=Hashsish Op= Opioids

Table 3

SOWS in different days in Topiramate and placebo groups

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **SOWS1** | **SOWS3** | **SOWS5** | **SOWS7** | **SOWS10** |
| z | -0.844 | -4.358 | -1.898 | -0.429 | -1.105 |
| p | 0.398 | 0.000 | 0.058 | 0.668 | 0.269 |
| Mean score(Placebo) | 54.15 | 53.75 | 37.25 | 25.63 | 20.17 |
| Mean score(Topiramate) | 54.67 | 52.22 | 35.82 | 25.34 | 20.18 |

Tabe 4

OOWS on different days in Topiramate and Placebo groups

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **OOWS1** | **OOWS3** | **OOWS5** | **OOWS7** | **OOWS10** |
| z | -0.494 | -4.407 | -2.913 | -2.220 | -1.932 |
| p | 0.621 | 0.000 | 0.004 | 0.026 | 0.053 |
| Mean score (Placebo) | 10.82 | 10.87 | 6.40 | 5.00 | 4.12 |
| Mean score (Topiramate) | 10.37 | 10.31 | 5.88 | 4.85 | 4.00 |

symptoms of patients were assessed in days 1,3,5,7 and 10.

Data was collected using 2 standard question- naires for assessment of withdrawal symptoms, Subjec- tive opiate withdrawal scale (SOWS) and objective opiate withdrawal scale (OOWS).

OOWS is an objective measure for intensity of opiate withdrawal symptoms. This scale is one part of initial assessment and is also used for rating the response to medication in the treatment course. This questionnaire has 13 questions which are graded as 0 (does not exist) or 1 (exist). So, the scores range between 0 to13.

SOWS is a self-report scale which has 16 ques- tions. These questions are graded in a likert scale from 0 (does not exist) to 4 (severe). The scores range be- tween 0 to 64.This questionnaire indicates the severity of withdrawal symptoms graded by the patient.

These scales have repeatedly been used in the different studies for assessment of withdrawal symp- toms19-22. Side effects of medications in 2 groups were assessed by a psychiatrist.

Collected data were described by descriptive sta- tistics and then were analyzed using the chi-square and t- test in the SPSS -11/5.

# RESULTS

Among the 149 patients 74 were in the Topiramate group and 75 were in the placebo group. Twenty-two patients 15 from placebo group and 7 from Topiramate group dropped –out during 10 days of study. Twenty patients did not tolerate the withdrawal symptoms and 2 subjects had psychosis.

Finally 127 patients completed the trial (60 in pla- cebo group and 67 in the Topiramate group).There were not significant differences between 2 groups in terms of mean age (p=0.147), sex distribution (p= 0.419), employment status (p= 0.379) and marriage (p=0.127). Results have been showed in table 1. Also 2 groups did not have significant differences in terms of the length of Heroin dependency (p=0.129), the way of Heroin con- sumption in one year before the study (p=0.455), his- tory of using alcohol (p=0.942), hashish (p=0.933) and other opiates except Heroin (p=0.756) (table 2).

Mann-whiteney test showed a significant differ- ence between 2 groups in terms of Subjective symp- toms of opioid withdrawal in SOWS. Patients in Topiramate group had less subjective symptoms on third day of detoxification compared to placebo group (P=0.000,Z=-4.358) (table 3). Based on Mann-whitney test there was a significant difference in 2 groups in objective symptoms of opioid withdrawal. These symp- toms were less in Topiramate group than placebo group on days 3(P=0.000,Z=-4.407),5(P=0.000,Z=-2.913) and 7 (P=0.026,Z=-2.220) (table 4).

The most common side effects of medication in both groups were speech difficulties (6 patients in pla- cebo and 7 in Topiramate group) and Ataxia (2 in pla- cebo and 9 in Toiramate group).Frequency of ataxia was significantly higher in patients receiving Topiramate com- pared to placebo group (P=0.021,x2=2.185).

# DISCUSSION

Neurophysiology of opioid withdrawal symptoms has not been recognized completely.

There are some neurotransmitter systems like no- radrenergic, colinergic, dopaminergic and glutaminergic

that have been proposed to be important in withdrawal symptoms of opioids.

The glutaminergic projection from paragiganto- cellularis to locus coeruleus (LC) activates the LC nora- drenergic cells that is related to symptoms of opioid with- drawal. N-Metyl-D-aspartic acid (NMDA) and Alpha – amino-3 hydroxy-5- methyl-4-isoxazole propionic acid (AMPA) receptors are important in this activation, but the role of AMPA is more important than the other one23. Topramate with inhibition of AMPA receptors reduces the activation of LC24 without any effect on NMDA recep- tors. It does not have PCP –like effects and seems to be an appropriate choice for alleviating opiate withdrawal symptoms. There are 2 studies in this area. The first one was mainly a case report that reported the efficacy of Topiramate in treating opiate withdrawal. In this study Topiramate was introduced at a dose of 500 mg/day and tapered to 100 mg/day on day 5 for 3 patients and was efficacious on more symptoms of the opiate withdrawal25.The second research in 2004 compared the withdrawal symptoms in 3 groups of 10 patients with opiate dependency receiving Topiramate, Carbamaze- pine/ Mianserin and Clonidine respectively. The results indicated that patients in Topiramate group needed less adjunctive medications like analgetics and muscular for their withdrawal symptoms. The authors concluded that Topiramate is a valuable drug for opiate detoxification26.

In the present study we had a large sample size in contrast to 2 previous researches in 2002(on 3 patients) and 2004(on 30 patients),so the results are more reli- able. The starting dose of Topiramate in our study was 75-100mg/day that is more appropriate for patients ‘com- pliance compared to the initiating dose of 500 mg/day in the research in2002.

In this study we used 2 scales (SOWS and OOWS) for evaluating the subjective and objective withdrawal symptoms of opioids. With more robust methodology, we found a significant difference in 2 groups in objective symptoms of opioid withdrawal. These symptoms were less in Topiramate group than placebo group on days 3(P=0.000,Z=-4.407), 5(P=0.000,Z=-2.913) and 7

(P=0.026,Z=-2.220). A significant difference was seen between 2 groups in terms of Subjective symptoms of opioid withdrawal in SOWS. Patients in Topiramate group had less subjective symptoms on third day of detoxifica- tion compared to placebo group (P=0.000,Z=-4.358). Because the most withdrawal symptoms of Heroin is seen in first 24-48 hours of withdrawal, the efficacy of Topiramate on third day seems to be more impor- tant.

Limitations of the present study include: examin- ing the inpatients only, not using Topiramate alone and also higher doses of Topiramate (for example, 500 mg/ day) for withdrawal symptoms. Further researches needs to be done on use of Topiramate alone, in comparison to other treatments for detoxification.

In conclusion, our study indicated that Topiramate added to usual treatment of opiate withdrawal is more efficacious than the usual treatment alone.

# ACKNOWLEDGEMENT

We thank Dr. Esmaili and Dr. Ardom for their in- valuable help.

# REFERENCES

1. Jaffe J, Strain EC, Opioid-Related Disorders. In: Sadock

B. Sadock V. Kaplan & Sadocks comprehensive text- book of psychiatry. 7th ed. Philadelphia: Lippincott Wil- liams & Wilkins; 2005. P. 1265-91

1. Koob GF, Maldonado R, Stinus L.Neural substrate of opiate withdrawal. Trend Neurosci 1992; 15: 186-91.
2. Trujillo KA, Akil H. Opiate tolerance and dependence recent finding and synthesis. New boil 1991; 3; 915-23.
3. Crystal is the first fetal opioid in iran. [Online] 2007. [Cited on 2007, September 18]. Available from URL: <http://incas.tums.ac.ir/news/detail.asp?newsI> D=167.
4. Gowing L, Ali R, White J. Alpha 2 adrenergic agonists for the management of opioid withdrawal.Cochrane Da- tabase Syst Rev. 2004 Oct 18;( 4):CD002025.
5. American Psychiatric Association. Practice guideline for the treatment of patients with substance use disorders: alcohol, cocaine, opioids. Am J Psychiatry 1995; 152: 43– 4.
6. Amato L, Davoli M, Ferri M, Gowing L, Perucci CA. Ef- fectiveness of interventions on opiate withdrawal treat- ment: an overview of systematic reviews. Drug Alcohol Depend 2004;73:219-26.
7. Amato L, Davoli M, Ferri M, Ali R. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2004 Oct 18;(4):CD003409
8. Jimenez Lerma JM, Landabaso M, Iraurgi L, Calle R, Sanz J, Gutierrez Fraile M. Nimodipine in opiate detoxi- fication: a controlled trial. Addiction 2002; 97: 819-24.
9. Herman D, Shamir R, Bar-Hamburger C, Pick S. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program— a randomized, double blind, placebo controlled, prospective study. Addict Behav 2005; 30:

1154-67.

1. Täschner KL. A controlled comparison of clonidine and doxepin in the treatment of the opiate withdrawal syn- drome. Pharmacopsychiatry 1986; 19:91-5.
2. Halikas JA , Kuhn KL. A possible neurophysiological basis of cocaine craving. Ann Clin Psychiatry 1990;2: 79–83.
3. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J.Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today 2004; 40:603-19.
4. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1990; 251: 85–7.
5. Lees G, Leech M J . Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993; 612**:** 190–9.
6. Rosen MI, Pearsall HR, Kosten TR. The effect of lamotrigine on naloxone-precipitated opiate withdrawal. Drug Alcohol Dependence 1998; 52: 173-6.
7. Martinez-Raga J, Sabater A, Perez-Galvez B, Castellano M, Cervera G.Add-on gabapentin in the treatment of opiate withdrawal.Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:599-601.
8. Bertschy G, Bryois C, Bondolfi A, Velardi A, Budry P, Dascal D, et al. The association carbamazepine mianserin in opiate withdrawal: a double blind pilot study versus clonidine. Pharmacol Res 1997; 35: 451–6.
9. Foltin RW, Fischman MW. Effects of methadone or buprenorphine maintenance on the subjective and rein- forcing effects of intravenous cocaine in humans. Am J Drug Alcohol Abuse 1996; 278: 1153-64.
10. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opi-

ate withdrawal. Am J Drug Alcohol Abuse 1987; 13:293- 308.

1. Loimer N, Linzmayer L, Grunberger J .Comparison be- tween observer assessment and self rating of withdrawal distress during opiate detoxification. Drug Alcohol de- pend 1991; 28:265-8.
2. Turkington D, Drummond DC .How should opiate with- drawal be measured? Drug Alcohol Depend 1989; 24:151-3.
3. Rasmussen K. The role of the locus coeruleus and N- methyl-d aspartic acid (NMDA) and AMPA receptors in Opiate Withdrawal. Neuropsychopharmacology 1995; 13: 295-300.
4. Langtry HD, Gillis JC , Davis R . Topiramate a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs1997; 54: 752–73.
5. Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal ;Progress in Neuro-Psychopharmacol Biol Psychiatry 2002; 26:1221-3.
6. Zullino DF, Krenz S, Zimmerman G, Miozzari A, Rajeswaran R, Kolly S, et al. Topiramate in opiate with- drawal-comparison with clonidine and with carbamazepine/mianserin. Subst Abus 2004; 25:27-33.